Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors

Circulation

Volumn 97, Issue 6, 1998, Pages 544-552

  Weitz, Jeffrey I ^a,b   Leslie, Beverly ^a   Hudoba, Monika ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Anticoagulants; Lasminogen activators; Thrombolysis; Thrombus

Indexed keywords

ALTEPLASE; ANTITHROMBIN; BG 8865; D DIMER; DEXTRO PHENYLALANYLPROLYLARGINYL CHLOROMETHYL KETONE; FIBRIN DEGRADATION PRODUCT; FIBRINOPEPTIDE A; HEPARIN; HIRUDIN; HIRUGEN; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOT LYSIS; BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; FIBRINOLYTIC THERAPY; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BINDING;

EID: 0031936090     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.6.544     Document Type: Article

References (51)

1. Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol. 1987;10:527-529.
2. Owen J, Friedman KD, Grossmann BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue-type plasminogen activator or streptokinase induces transient thrombin activity. Blood. 1988;72:616-620.
3. Rapold JH, Kuemmerli H, Weiss M, Baur H, Haeberli A. Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation. 1989;79:980-989.
4. Rapold JH. Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation. Lancet. 1990;1:481-482.
5. Rapold HJ, Grimaudo V, Derclerck PJ, Kruithof EKO, Bachmann F. Plasma levels of plasminogen activator inhibitor type 1, β-thromboglobulin, and fibrinopeptide A before, during, and after treatment of acute myocardial infarction with alteplase. Blood. 1991;78:1490-1495.
6. Cairns JA, Fuster V, Gore J, Kennedy JW. Coronary thrombolysis. Chest. 1995;108:401-423.
7. Ewald GA, Eisenberg PR. Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. Circulation. 1995;91:28-36.
8. Lee CD, Mann KG. The activation of human coagulation factor V by plasmin. Blood. 1989;73:185-190.
9. Eisenberg PR, Miletich JP, Sobel BE, Jaffe AS. Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA). Thromb Res. 1988;50:707-717.
10. Seitz R, Pelzer H, Immel A, Egbring R. Prothrombin activation by thrombolytic agents. Fibrinalysis. 1993;7:109-115.
11. Mirshahi M, Soria J, Soria C, Faivre F, Lu H, Courtney M, Roitsch C, Tripier D, Caen JP. Evaluation of the inhibition by heparin and hirudin of coagulation activation during rt-PA-induced thrombolysis. Blood. 1989;74:1026-1030.
12. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin- anrithrombin III: implications for heparin efficacy. Proc Natl Acad Sci U S A. 1989;86:3619-3623.
13. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound chrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
14. Kumar R, Beguin S, Hemker C. The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity. Thromb Haemost. 1995;74:962-968.
15. Kumar R. Beguin S, Hemker HC. The influence of fibrinogen and fibrin on thrombin generation: evidence for feedback activation of the clotting system by clot bound thrombin. Thromb Haemost. 1994;72:713-721.
16. Bloom AL. The release of thrombin from fibrin by fibrinolysis. Br J Haematol. 1962;8:129-133.
17. Weitz JI, Cruickshank MK, Thong B, Leslie B, Levine MN, Eckhardt T. Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen. J Clin Invest. 1988;82:1700-1707.
18. Maraganore J, Chao B, Joseph ML, Jablonski J, Ramachandran KL. Anticoagulant activity of synthetic hirudin peptides. J Biol Chem. 1989;264:8692-8698.
19. 125I-fibrinogen injection. J Radioanal Chem. 1981;65:179-188.
20. McFarlane AS. Labelling of plasma proteins with radioactive iodine. Biochem J. 1956;62:135-143.
21. Francis CW, Marder VJ, Martin SE. Plasmic degradation of crosslinked fibrin, I: structural analysis of the particulate clot and identification of new macromolecular-soluble complexes. Blood. 1980;56:456-464.
22. Nossel HL, Yudelman I, Canfield RE, Butler VP Jr, Spanondis K, Wilner CD, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest. 1974;54:43-53.
23. Weitz JI, Leslie B, Ginsberg J. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis. J Clin Invest. 1991;87:1082-1090.
24. MacGregor IR, Micklem LR, James K, Pepper DS. Characterization of epitopes on human tissue plasminogen activator recognized by a group of monoclonal antibodies. Thromb Haemost. 1985;53:45-50.
25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265-275.
26. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond). 1970;227:680-685.
27. Davis BJ. Disc electrophoresis, II: method and application to human serum proteins. Ann N Y Acad Sci. 1964;121:404-427.
28. Winer BJ. Statistical principles in experimental design. 2nd ed. New York, NY: McGraw-Hill; 1962:149-599.
29. Meh DA, Siebenlist KR, Mosesson MW. Identification and characterization of the thrombin binding sites on fibrin. J Biol Chem. 1996;271:23121-23125.
30. Binnie CG, Lord ST. A synthetic analog of fibrinogen α 27 to 50 is an inhibitor of thrombin. Thromb Haemost. 1991;65:165-168.
31. Francis CW, Markham RE Jr, Barlow GH, Florack TM, Dobrzymki DM, Marder VJ. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med. 1983;102:220-230.
32. Gast A, Tschopp TB, Schmid G, Hilpert K, Ackerman J. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46 to 6240). recombinant hirudin and heparin in human plasma. Blood Coagul Fibrinolysis. 1994;5:879-887.
33. Hirsh J. Heparin. N Engl J Med. 1991;324:1565-1574.
34. Hirsh J, vanArken WG, Gallus AS, Dollery CG, Cade JS, Young WG. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation. 1976;53:691-695.
35. Eisenberg PR, Sherman L, Rich M, Schwartz D, Schechtman K, Geltman EM, Sobel BE, Jaffe AS, Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol. 1986;7:1253-1262.
36. Rapold HJ, deBono D, Arnold AER, Arnout J, DeCock F, Collen D, Verstraete M, for the European Cooperative Study Group. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase: correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. Circulation. 1992;85:928-934.
37. Prager NA, Abendschein DR, McKenzie CR, Eisenberg PR. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation. 1995;92:962-967.
38. Danielsson A, Raub E, Lindahl U, Bjork I. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem. 1986;261:15467-15473.
39. Olson ST. Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III: linkage of protease-inhibitor-heparin interactions in the reaction with thrombin. J Biol Chem. 1988;263:1698-1708.
40. Seegers WH, Nieff M, Shafer JA. Note on the adsorption of thrombin on fibrin. Science. 1945;101:520-521.
41. Liu CY, Nossel HL, Kaplan KL. The binding of thrombin by fibrin. J Biol Chem. 1979;254:10421-10425.
42. Wilner GD, Danitz MP, Mudd MS, Hsieh KH, Fenton JW II. Selective immobilization of thrombin by surface bound fibrin. J Lab Clin Med. 1981;97:403-411.
43. Berliner LJ, Sugawara Y, Fenton JW II. Human α-thrombin binding to nonpolymerized fibrin-Sepharose; evidence for an anionic binding region. Biochemistry. 1985;27:7005-7009.
44. Kaminski M, McDonagh J. Inhibited thrombins: interactions with fibrinogen and fibrin. Biochem J. 1987;242:881-887.
45. 2CI: A selective affinity label for thrombin. Thromb Res. 1979;14:969-973.
46. Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton JW. The structure of a complex of recombinant hirudin and human α-thrombin. Science. 1990;249:277-280.
47. Klement P, Borm A, Hirsh J, Maraganore J, Wilson G, Weitz J. The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model. Thromb Haemost. 1992;68:64-68.
48. Lidon RM, Theroux P, Lesperance J, Adelman B, Bonan R, Duval D, Levesque J. A pilot early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation. 1994;89:1567-1572.
49. Theroux P, Perez-Villa F, Waters D, Lesperance J, Shabani F, Bonan R. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation. 1995; 91:2132-2139.
50. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwald E. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol. 1994;23:993-1003.
51. GUSTO Investigators. A comparison of recombinant hirudin with heparin for treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. N Engl J Med. 1996;335:775-782.